HIVE vs BTBT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

HIVE

65.2
AI Score
VS
HIVE Wins

BTBT

63.0
AI Score

Investment Advisor Scores

HIVE

65score
Recommendation
BUY

BTBT

63score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE BTBT Winner
Revenue 164.00M 87.11M HIVE
Net Income -221.61M -225.38M HIVE
Net Margin -135.1% -258.7% HIVE
ROE -60.8% -41.8% BTBT
ROA -25.8% -13.1% BTBT
Total Assets 857.69M 1.72B BTBT
Cash 138.99M 143.47M BTBT
Current Ratio 1.55 1.36 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: -26.2% · 3M: -32.2% BTBT 1M: -34.3% · 3M: -46.7%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 36

RSI (14): 35.9 · Price: $1.75

BTBT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 39

RSI (14): 38.6 · Price: $0.79

Fundamentals Snapshot

Metric HIVE BTBT
Market Cap — —
Forward P/E -3.4 -5.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.7% 0.3%
Gross Margin 0.4% 0.6%
Operating Margin -0.6% -2.4%
EPS -1.53 -1.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.